DGIdb - CYP2B6 Gene Record

CYP2B6 1555 Druggable Genome

Alternate Names:

1555
CYTOCHROME P450 FAMILY 2 SUBFAMILY B MEMBER 6
CYP2B6
CPB6
CYP2B
CYP2B7
CYP2B7P
CYPIIB6
EFVM
IIB1
P450
123930
2615
ENSG00000197408
OTTHUMG00000182714
CYTOCHROME P450 2B6 (EC 1.14.14.1) (CYPIIB6) (P450 IIB1). [SOURCE:UNIPROT/SWISSPROT;ACC:P20813]
PA123
P20813
CP2B6_HUMAN
CYTOCHROME P450 2B6

Gene Info:

Human Readable Name	DRUGGABLE GENOME
Interpro Short Name	Cyt_P450
Interpro Acc	IPR001128
Interpro Name	Cytochrome P450
Uniprot Evidence	1: Evidence at protein level
Uniprot Status	Swiss-Prot
Human Readable Name	CYTOCHROME P450
Interpro Type	Family
Gene Biotype	PROTEIN_CODING

(5 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME
CYTOCHROME P450
ENZYME

Publications:

Lang T et al., 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver., Pharmacogenetics
Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
Sridar C et al., 2012, Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein., Drug Metab Dispos
D'Avolio A et al., 2013, Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane., Pharmacogenet Genomics
Victorri-Vigneau C et al., 2019, Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study., Br J Clin Pharmacol
Mactier H et al., 2017, Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers., Am J Perinatol
Zahari Z et al., 2016, Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT)., Drug Alcohol Depend
Csajka C et al., 2016, Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients., Clin Pharmacokinet
Mouly S et al., 2015, Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity., Br J Clin Pharmacol
Dobrinas M et al., 2013, Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study., Pharmacogenet Genomics
Hung CC et al., 2011, Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients., Pharmacogenomics
Levran O et al., 2013, CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction., Addict Biol
Uehlinger C et al., 2007, Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients., J Clin Psychopharmacol
Eap CB et al., 2007, Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers., Clin Pharmacol Ther
Crettol S et al., 2006, ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment., Clin Pharmacol Ther
Crettol S et al., 2005, Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment., Clin Pharmacol Ther
Amunugama HT et al., 2012, Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme., Drug Metab Dispos
Jeong S et al., 2009, Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A., Antimicrob Agents Chemother
Habtewold A et al., 2013, Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients., Pharmacogenomics J
Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics
Abell LM et al., 2011, Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro., J Pharmacol Exp Ther
Faucette et al., 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers., Drug Metab. Dispos.
Gong L et al., 2014, PharmGKB summary: tramadol pathway., Pharmacogenet Genomics
Wang Y et al., 2017, Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population., Infect Genet Evol
Cho DY et al., 2016, Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers., Drug Metab Pharmacokinet
Garcia KL et al., 2015, Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration., Neuropsychopharmacology
Ring HZ et al., 2007, Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism., Pharmacogenet Genomics
Johnstone E et al., 2006, Determinants of the rate of nicotine metabolism and effects on smoking behavior., Clin Pharmacol Ther
McKillop et al., 1998, Enzyme-inducing effects of bicalutamide in mouse, rat and dog., Xenobiotica
Chang et al., 1993, Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes., Cancer Res.
Chen et al., 2005, Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450., Drug Metab. Dispos.
Braybrooke et al., 2005, Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma., Clin. Cancer Res.
van Schaik, 2004, Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents., Ther Drug Monit
Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
Shu W et al., 2017, Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma., J Clin Pharmacol
Veal GJ et al., 2016, Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma., Eur J Cancer
Johnson GG et al., 2013, CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia., Blood
Ariyoshi N et al., 2011, Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262., Drug Metab Dispos
Bray J et al., 2010, Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide., Br J Cancer
Rocha V et al., 2009, Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia., Leukemia
May-Manke et al., 1999, Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide., Cancer Chemother. Pharmacol.
Dvorak et al., 2003, Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation., Mol. Pharmacol.
Ciccacci C et al., 2017, Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility., Eur J Clin Pharmacol
Olagunju A et al., 2016, Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study., Pharmacogenet Genomics
Ciccacci C et al., 2013, Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study., Eur J Clin Pharmacol
Heil SG et al., 2012, Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals., Ther Drug Monit
Lehr T et al., 2011, Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine., Pharmacogenet Genomics
Gozalo C et al., 2011, Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial., Basic Clin Pharmacol Toxicol
Yuan J et al., 2011, Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent., AIDS
Chen J et al., 2010, CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients., Ther Drug Monit
Ciccacci C et al., 2010, Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique., Pharmacogenomics
Mahungu T et al., 2009, Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population., HIV Med
Rotger M et al., 2005, Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients., Pharmacogenet Genomics
Faucette et al., 2007, Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers., J. Pharmacol. Exp. Ther.
Thorn CF et al., 2011, PharmGKB summary: carbamazepine pathway., Pharmacogenet Genomics
Roy et al., 1995, Human liver oxidative metabolism of O6-benzylguanine., Biochem. Pharmacol.
Kassogue Y et al., 2014, Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib., Med Oncol
Jaquenoud Sirot E et al., 2012, Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression., J Clin Psychopharmacol
Uppugunduri CR et al., 2014, The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation., Pharmacogenomics J
Rendic et al., 1999, Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites., J. Chromatogr. B Biomed. Sci. Appl.
Li Y et al., 2015, CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects., Br J Clin Pharmacol
Yuce-Artun N et al., 2016, Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients., Int J Clin Pharm

TROFOSFAMIDE CYP2B6

Interaction Score: 2.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10447581

Sources:
NCI
KETAMINE CYP2B6

Interaction Score: 1.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25702819 11470993 17638512

Sources:
PharmGKB
MEPERIDINE CYP2B6

Interaction Score: 0.97

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11470993 17638512

Sources:
PharmGKB
NEVIRAPINE CYP2B6

Interaction Score: 0.9

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28689274 27195527 23774940 22354160 21860339 21824325 21505298 20625352 20017669 19228205 15864119 11470993 17638512 17041008

Sources:
NCI PharmGKB
METHADONE CYP2B6

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30907440 28320034 27289271 27286724 25556837 23249875 21902500 21790905 17502774 17329992 17178267 16338275 11470993 17638512 22685215

Sources:
DTC PharmGKB
ETHAMBUTOL CYP2B6

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28389387

Sources:
PharmGKB
OSPEMIFENE CYP2B6

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
ARTEMISININ CYP2B6

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11470993 17638512

Sources:
PharmGKB
6-O-BENZYLGUANINE CYP2B6

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7503788

Sources:
NCI
PRASUGREL CYP2B6

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21828263

Sources:
PharmGKB FDA
IFOSFAMIDE CYP2B6

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11470993 17638512

Sources:
PharmGKB
SELEGILINE CYP2B6

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11470993 17638512

Sources:
PharmGKB
BICALUTAMIDE CYP2B6

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9622849

Sources:
NCI
VORICONAZOLE CYP2B6

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19029318

Sources:
DTC
MEPHENYTOIN CYP2B6

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11470993 17638512

Sources:
PharmGKB
PYRAZINAMIDE CYP2B6

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28389387

Sources:
PharmGKB
THIOTEPA CYP2B6

Interaction Score: 0.32

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
17638512

Sources:
PharmGKB
MITOTANE CYP2B6

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23524664

Sources:
PharmGKB
RIFAMPIN CYP2B6

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28389387 27053325 17638512

Sources:
PharmGKB
COTININE CYP2B6

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18004205

Sources:
PharmGKB
ARTEMETHER CYP2B6

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CYCLOPHOSPHAMIDE CYP2B6

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8242617 15919850 15746054 15228172 29938344 28181240 26773420 24128861 21821736 20179710 19005482 11470993 17638512

Sources:
NCI PharmGKB
TICLOPIDINE CYP2B6

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
17638512

Sources:
PharmGKB
ISONIAZID CYP2B6

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28389387

Sources:
PharmGKB
CHEMBL530733 CYP2B6

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
EFAVIRENZ CYP2B6

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17041008

Sources:
NCI FDA
STAVUDINE CYP2B6

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23089673

Sources:
PharmGKB
NICOTINE CYP2B6

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25652250 18004205 17015050 11470993 17638512

Sources:
PharmGKB
BUSULFAN CYP2B6

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24165757

Sources:
PharmGKB
FLIBANSERIN CYP2B6

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
TRAMADOL CYP2B6

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24849324

Sources:
PharmGKB
CARBAMAZEPINE CYP2B6

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14977870 21738081 17638512

Sources:
NCI PharmGKB
PHENOBARBITAL CYP2B6

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14977870 17638512

Sources:
NCI PharmGKB
RITONAVIR CYP2B6

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14977870

Sources:
NCI
MIRTAZAPINE CYP2B6

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22926595

Sources:
PharmGKB
DIAZEPAM CYP2B6

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11470993 17638512

Sources:
PharmGKB
SERTRALINE CYP2B6

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26830411

Sources:
PharmGKB
MIDAZOLAM CYP2B6

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11470993 17638512

Sources:
PharmGKB
LAMIVUDINE CYP2B6

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23089673

Sources:
PharmGKB
ZIDOVUDINE CYP2B6

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23089673

Sources:
PharmGKB
TESTOSTERONE CYP2B6

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10630892

Sources:
NCI
PHENYTOIN CYP2B6

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17638512

Sources:
PharmGKB
CLOPIDOGREL CYP2B6

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
COLCHICINE CYP2B6

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12815172

Sources:
NCI
TAMOXIFEN CYP2B6

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22942317

Sources:
DTC
DOXORUBICIN CYP2B6

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 20179710

Sources:
PharmGKB
IMATINIB CYP2B6

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24293093

Sources:
PharmGKB
SORAFENIB CYP2B6

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28362716

Sources:
PharmGKB

Ensembl: ENSG00000197408
- Version: 101_38
Alternate Names:

CYP2B6 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
RussLampel: ENSG00000197408
- Version: 26-July-2011
Alternate Names:

CYP2B6 Display Id

CYTOCHROME P450 2B6 (EC 1.14.14.1) (CYPIIB6) (P450 IIB1). [SOURCE:UNIPROT/SWISSPROT;ACC:P20813] Description

ENSG00000197408 Ensembl Gene Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:
HopkinsGroom: P20813
- Version: 11-September-2012
Alternate Names:

ENSG00000197408 Ensembl Gene Id

CYP2B6 Uniprot Gene Name

P20813 Uniprot Accession

Gene Info:

Interpro Acc IPR001128

Interpro Name Cytochrome P450

Uniprot Evidence 1: Evidence at protein level

Gene Categories:

DRUGGABLE GENOME, CYTOCHROME P450

Publications:

PharmGKB: CYP2B6

Version: 18-August-2020

Alternate Names:

PA123 PharmGKB ID

Gene Info:

Publications:

Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics

Lang T et al., 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver., Pharmacogenetics

Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics

NCI: CYP2B6

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

May-Manke et al., 1999, Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide., Cancer Chemother. Pharmacol.

Rendic et al., 1999, Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites., J. Chromatogr. B Biomed. Sci. Appl.

Faucette et al., 2007, Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers., J. Pharmacol. Exp. Ther.

DTC: CYP2B6

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Jeong S et al., 2009, Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A., Antimicrob Agents Chemother

Amunugama HT et al., 2012, Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme., Drug Metab Dispos

Sridar C et al., 2012, Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein., Drug Metab Dispos

HingoraniCasas: ENSG00000197408
- Version: 31-May-2017
Alternate Names:

ENSG00000197408 Gene Symbol

CYP2B6 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
Pharos: CYP2B6
- Version: 01-February-2022
Alternate Names:

Cytochrome P450 2B6 Gene Name

P20813 UniProt ID

Gene Info:

Gene Categories:

ENZYME

Publications:
FDA: CYP2B6
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:

CYP2B6	Display Id
CYTOCHROME P450 2B6 (EC 1.14.14.1) (CYPIIB6) (P450 IIB1). [SOURCE:UNIPROT/SWISSPROT;ACC:P20813]	Description
ENSG00000197408	Ensembl Gene Id

CYP2B6 Gene Record

CYP2B6 1555 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10447581

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25702819 11470993 17638512

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11470993 17638512

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28689274 27195527 23774940 22354160 21860339 21824325 21505298 20625352 20017669 19228205 15864119 11470993 17638512 17041008

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30907440 28320034 27289271 27286724 25556837 23249875 21902500 21790905 17502774 17329992 17178267 16338275 11470993 17638512 22685215

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28389387

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11470993 17638512

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7503788

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21828263

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11470993 17638512

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11470993 17638512

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9622849

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19029318

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11470993 17638512

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28389387

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 17638512

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23524664

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

PMIDs:
10447581

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25702819 11470993 17638512

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11470993 17638512

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28689274 27195527 23774940 22354160 21860339 21824325 21505298 20625352 20017669 19228205 15864119 11470993 17638512 17041008

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30907440 28320034 27289271 27286724 25556837 23249875 21902500 21790905 17502774 17329992 17178267 16338275 11470993 17638512 22685215

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28389387

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
11470993 17638512

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
7503788

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21828263

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
11470993 17638512

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11470993 17638512

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9622849

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
19029318

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
11470993 17638512

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28389387

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
17638512

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23524664

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28389387 27053325 17638512

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18004205

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
8242617 15919850 15746054 15228172 29938344 28181240 26773420 24128861 21821736 20179710 19005482 11470993 17638512

Sources:
NCI PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
17638512

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28389387

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
17041008

Sources:
NCI FDA

Interaction Types & Directionality:

n/a

PMIDs:
23089673